The combination of adverse effects and interaction between comorbidity and pharmacotherapies, such as renin–angiotensin–aldosterone system inhibitors (RAASi), justify a systematic understanding of this common complication of CKD. The gene discussed is REN; the disease is chronic kidney disease.